POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
21 hedge funds and large institutions have $198M invested in POINT Biopharma Global Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 14 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
33% more capital invested
Capital invested by funds: $149M → $198M (+$48.9M)
25% less funds holding
Funds holding: 28 → 21 (-7)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$24.4M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$20.3M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.2M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$10.2M |
| 5 |
JJIJ
Johnson & Johnson Innovation - JJDC
New Brunswick,
New Jersey
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$10.5M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$10.5M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$10.5M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.25M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.25M |
PNT Hedge Fund Activity: Q2 2021 in Review
21 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q2 2021, worth a combined $198M — up 33% from $149M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PNT and 7 opened new positions — a net loss of 7 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $24.4M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $10.5M sold.
- 21 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q2 2021, down from 28 in Q1 2021.
- Funds reported $198M of POINT Biopharma Global Inc. Common Stock stock for Q2 2021, up 33% quarter-over-quarter.
- 7 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q2 2021 and 14 closed out, a net change of -7 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q2 2021 was Farallon Capital Management, an estimated $24.4M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q2 2021 was Avoro Capital Advisors, an estimated $10.5M sold.
Based on aggregated 13F filings for Q2 2021.